<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Commenti a: Sarepta Therapeutics annuncia l’autorizzazione della domanda di richiesta per un nuovo farmaco -Investigational New Drug (IND)-da parte della U.S. Food and Drug Administration (FDA) per il candidato PPMO dell’esone 51, SRP-5051	</title>
	<atom:link href="https://www.parentproject.it/2017/11/10/sarepta-therapeutics-annuncia-lautorizzazione-della-domanda-di-richiesta-per-un-nuovo-farmaco-investigational-new-drug-ind-da-parte-della-u-s-food-and-drug-administration-fda-per-il-can/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.parentproject.it/2017/11/10/sarepta-therapeutics-annuncia-lautorizzazione-della-domanda-di-richiesta-per-un-nuovo-farmaco-investigational-new-drug-ind-da-parte-della-u-s-food-and-drug-administration-fda-per-il-can/</link>
	<description>Insieme per fermare la Duchenne e la Becker</description>
	<lastBuildDate>Fri, 10 Nov 2017 11:07:15 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>
</channel>
</rss>
